Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Moderate to Severe Atopic Dermatitis
NCT03568136Phase 2Completed
- Sponsor
- GWT-TUD
- Start
- Sep 2018
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of secukinumab in atopic dermatitis (AD), sponsored by GWT-TUD. Started Sep 2018; status: completed.
02
Drugs
secukinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03568136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03568136.